Experimental CAR-T therapy targets Hard-to-Treat brain cancer

NCT ID NCT07062627

Recruiting now Disease control Sponsor: Hyungwoo Cho Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing a new treatment called Anbal-cel for people with relapsed or refractory primary or secondary central nervous system lymphoma. Anbal-cel is a CAR-T cell therapy made from the patient's own immune cells. The study will enroll 12 participants to see if the treatment is safe and effective. Participants will receive a single infusion of Anbal-cel and be monitored closely for at least 7 days in the hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anbal-cel (a CAR-T cell therapy made from the patient's own immune cells)
What this could lead to: If successful, this could offer a new treatment option for patients with hard-to-treat central nervous system lymphoma that has come back or not responded to other therapies.
What could go wrong: This is a very small pilot study with only 12 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) PRIMARY CNS LYMPHOMA (PCNSL)

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.